*The treatment process includes leukapheresis, manufacturing, administration, and adverse event monitoring. A single dose of ABECMA contains a cell suspension of 300 to 510 x 106 CAR-positive T cells in 1 or more infusion bags.

ABECMA is a one-time infusion* created just for you

ABECMA, a CAR T cell therapy, uses cells from your body's immune system to fight multiple myeloma. ABECMA uses T cells that have been reprogrammed to find and destroy specific target cells, which may include cancer cells and normal cells.

One type of immune cell is the T cell, which helps to fight off harmful diseases that can make you sick. T cells do this by using hooks on their surfaces called receptors, as explained in the diagram below.

How ABECMA is made

T cells

YOUR T CELLS

T cells are a type of immune cell that help the body fight off diseases, including cancer

With the addition of
CARs

CARs

CARs are “hooks” (receptors) that
are added to
your T cells

Results in
T cells and CARs combined to create ABECMA® (idecabtagene vicleucel)

ABECMA

Your newly made CAR T cells that are powered to find and fight multiple myeloma cells

ABECMA cells are created by adding new hooks, called chimeric antigen receptors (CARs), to your existing T cells. This makes them better able to attach to multiple myeloma cells and destroy them. ABECMA can also target normal, healthy cells.

Here’s how ABECMA works

Inside your body, ABECMA CAR T cells look for a protein found on multiple myeloma cells called a B-cell maturation antigen, or BCMA. It may be found on some healthy cells, too. Once found, your ABECMA CAR T cells attach to the multiple myeloma cells and destroy them.

ABECMA® (idecabtagene vicleucel) CAR T cell attaching itself to a BMCA protein on the outside of myeloma cell ABECMA® (idecabtagene vicleucel) CAR T cell attaching itself to a BMCA protein on the outside of myeloma cell

Find out if ABECMA
may be right for you

see if it’s time for abecma

Hear from real people who have been treated with ABECMA

watch stories